# Compare MOTS-c and Tesamorelin — TSMMA Peptides

> A side-by-side comparison of two Metabolic & Weight Research peptides — MOTS-c and tesamorelin — across peptide class, evidence base, administration studied, regulatory status and key cautions.

Where MOTS-c and tesamorelin converge on metabolic targets, and where they diverge sharply — in species studied, regulatory standing, and the depth of the clinical record.

## The short version

This page lines up [MOTS-c](/mots-c) and [tesamorelin](/tesamorelin) on the dimensions that matter most when reading research peptides: what kind of molecule each one is, where it has been most studied, how strong that evidence is, how it was administered in studies, its regulatory standing, and its single biggest caution. The headline is stark. Both peptides affect metabolic regulation, but they are at opposite ends of the clinical-evidence spectrum: tesamorelin has completed multiple Phase 3 randomized controlled trials and holds an FDA approval (for HIV-associated lipodystrophy specifically), while MOTS-c has no published human efficacy trial of any kind — only observational biomarker associations and a deep, coherent animal record. Neither is presented here with a human dose.

## The comparison matrix

| Dimension | MOTS-c | Tesamorelin |
| --- | --- | --- |
| Peptide class | Mitochondrial-derived peptide (MDP), 16 aa, encoded in MT-RNR1 | Synthetic GHRH analogue, 44 aa, N-terminal trans-3-hexenoyl modification |
| Most-studied in | Skeletal muscle insulin sensitivity; exercise-mimetic effects; aging | Visceral fat reduction in HIV-associated lipodystrophy; hepatic fat; GH/IGF-1 axis |
| Evidence base (model) | Rodents + human biomarker association cohorts; no human efficacy trial [3][2] | Five Phase 3 RCTs in HIV-positive adults; one 52-week controlled trial [8][12] |
| Administration studied | Subcutaneous or intraperitoneal injection in rodents; no validated human PK | Subcutaneous injection, 2 mg/day, in human RCTs [10][11] |
| Regulatory / WADA status | Not approved; WADA-prohibited (peptide/metabolic-modulator) | FDA-approved (NDA 022505, HIV lipodystrophy only); WADA S2 prohibited |
| Key caution | No human efficacy trial; no validated human PK; population differences in effect [3] | Approval limited to HIV lipodystrophy; fat reaccumulates on stopping; IGF-1 elevation [9][12] |

## Peptide class

The two peptides come from strikingly different origins. MOTS-c is an endogenous signaling peptide of 16 amino acids, encoded not in nuclear DNA but in the mitochondrial 12S rRNA gene (MT-RNR1) — making it one of a small class of mitochondrial-derived peptides the body produces itself in response to exercise and metabolic stress [3][6]. Tesamorelin is a fully synthetic 44-amino-acid analogue of a natural hypothalamic hormone, engineered with a trans-3-hexenoyl group on its N-terminus to resist rapid enzymatic breakdown [9]. MOTS-c is something the body already makes; tesamorelin is a drug designed to mimic and extend a natural hormonal signal.

## Most-studied in

Each peptide has a clearly established research territory. MOTS-c has been studied most in skeletal-muscle metabolic function — specifically AMPK activation, glucose uptake, and insulin sensitivity — and in the context of exercise physiology and aging-related physical decline [4][6]. Tesamorelin's research is concentrated in a defined clinical population: HIV-positive adults on antiretroviral therapy who have developed lipodystrophy (abnormal visceral fat accumulation), where it acts via the GH/IGF-1 axis to preferentially reduce visceral and hepatic fat [8][10].

## Evidence base (model)

The evidence gap is the defining feature of this comparison. Tesamorelin is supported by a meta-analysis of five RCTs in 273-plus treated subjects, multiple 6- and 52-week controlled trials with objective imaging endpoints, and a dedicated pharmacokinetics study in healthy men [8][10][11][12]. MOTS-c is supported by rigorous mechanistic cell work, a compelling exercise-performance mouse study [4], a cardiac metabolic model in diabetic rats [7], and prospective human cohort data showing that circulating MOTS-c levels predict mortality in hemodialysis patients [2] — but none of those human studies gave MOTS-c to anyone. The entire human interventional record for MOTS-c is empty.

## Administration studied

Administration routes track the state of clinical development. Tesamorelin is administered subcutaneously at 2 mg/day in every human trial, and human pharmacokinetics in healthy men have been formally measured [11]. MOTS-c has been given subcutaneously or intraperitoneally in rodent research; there is no published measurement of MOTS-c pharmacokinetics in humans — half-life, bioavailability, and dosing interval are entirely unknown in the clinical context [3].

## Regulatory / WADA status

Tesamorelin is FDA-approved (NDA 022505, November 2010) for a specific HIV lipodystrophy indication — making it the only peptide on this desk with a completed regulatory approval. That approval is narrow: it does not extend to general visceral-fat reduction, obesity management, or any non-HIV metabolic condition [9]. Both peptides are prohibited in sport: tesamorelin under WADA Prohibited List category S2 (peptide hormones, growth factors, related substances and mimetics), and MOTS-c under WADA's metabolic-modulator/peptide categories. Neither is an approved supplement or over-the-counter product.

## Key caution

Each peptide carries its own defining caveat. For MOTS-c it is the complete absence of human efficacy or safety trial data: a peptide with a compelling preclinical story and a coherent mechanism that has not yet been tested in a human interventional study [3]. For tesamorelin the caution is the inverse: it *has* been tested, and it works — but benefits require ongoing dosing (fat reaccumulates on stopping [12]), its approval is specific to one clinical population, and IGF-1 elevation warrants monitoring in anyone with cancer history or metabolic risk [9]. Read together, the two peptides define the range from "well-mechanized preclinical promise" to "narrow but real clinical proof." Neither licenses self-administration.

---

A literature digest tracing two metabolic signals from mitochondria and pituitary to the edge of clinical evidence — citations only, never a clinic, never a vendor.